Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

Key Takeaways AMGN's Q2 revenues rose 9% Y/Y to $9.2B, driven by strong volume growth across key drug portfolios.Repatha, Evenity, Blincyto and rare disease drugs led gains, offsetting pricing pressure and legacy declines.Biosimilars surged 40% Y/Y to $661M, with new launches like Pavblu contributing.Amgen (AMGN) delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance.Amgen’s total ...